GEP20063752B - Humanized Anti-LT-Beta-R Antibodies - Google Patents

Humanized Anti-LT-Beta-R Antibodies

Info

Publication number
GEP20063752B
GEP20063752B GE5165A GEAP2001005165A GEP20063752B GE P20063752 B GEP20063752 B GE P20063752B GE 5165 A GE5165 A GE 5165A GE AP2001005165 A GEAP2001005165 A GE AP2001005165A GE P20063752 B GEP20063752 B GE P20063752B
Authority
GE
Georgia
Prior art keywords
beta
antibody
humanized anti
solid tumors
reducing
Prior art date
Application number
GE5165A
Other languages
English (en)
Inventor
Ellen A Garber
Paul D Lyne
Jose W Saldanha
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of GEP20063752B publication Critical patent/GEP20063752B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GE5165A 2000-10-13 2001-10-12 Humanized Anti-LT-Beta-R Antibodies GEP20063752B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
GEP20063752B true GEP20063752B (en) 2006-02-27

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
GE5165A GEP20063752B (en) 2000-10-13 2001-10-12 Humanized Anti-LT-Beta-R Antibodies

Country Status (25)

Country Link
US (2) US7429644B2 (de)
EP (1) EP1326897A2 (de)
JP (1) JP2004532608A (de)
KR (1) KR20030041164A (de)
CN (1) CN1547590A (de)
AR (1) AR035352A1 (de)
AU (2) AU1174702A (de)
BG (1) BG107802A (de)
BR (1) BR0114646A (de)
CA (1) CA2425809A1 (de)
CZ (1) CZ20031307A3 (de)
EA (1) EA006945B1 (de)
EE (1) EE200300179A (de)
GE (1) GEP20063752B (de)
HU (1) HUP0302573A2 (de)
IL (1) IL155340A0 (de)
IS (1) IS6779A (de)
MX (1) MXPA03003144A (de)
NO (1) NO20031642L (de)
NZ (1) NZ525793A (de)
PL (1) PL366307A1 (de)
SK (1) SK5672003A3 (de)
TR (2) TR200602095T2 (de)
WO (1) WO2002030986A2 (de)
YU (1) YU28503A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
PE20080262A1 (es) * 2006-05-25 2008-04-30 Glaxo Group Ltd Anticuerpo humanizado contra interleuquina-18
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
JP5298021B2 (ja) * 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101653599A (zh) * 2006-10-20 2010-02-24 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
CA2667997C (en) 2006-11-02 2016-10-11 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
HUE027507T2 (en) 2007-06-25 2016-10-28 Esbatech Alcon Biomed Res Unit Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CA2920666A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. Compositions and method for treating complement-associated conditions
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
EP3611188B1 (de) 2014-11-06 2022-05-04 F. Hoffmann-La Roche AG Fc-region-varianten mit modifizierter fcrn-bindung und verfahren zur verwendung
BR112018000653A2 (pt) 2015-07-14 2018-09-18 Immunext Inc anticorpo anti-cd154 tendo características melhoradas de ligação, funcionais e de segurança e uso na imunoterapia humana
EP3368090A1 (de) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CN115087670A (zh) 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
AR128031A1 (es) 2021-12-20 2024-03-20 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69132629T2 (de) 1990-06-27 2002-04-18 Biogen Inc Oberflächenkomplexbildung von lymphotoxin
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE397665T1 (de) 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CN1146442C (zh) * 1995-01-26 2004-04-21 拜奥根有限公司 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CA2319698A1 (en) 1998-01-30 1999-08-05 Biogen, Inc. Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
WO2004002431A2 (en) 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
JP2006513225A (ja) 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
CN100473664C (zh) 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途

Also Published As

Publication number Publication date
US20090092601A1 (en) 2009-04-09
AR035352A1 (es) 2004-05-12
WO2002030986A3 (en) 2003-03-13
US7429644B2 (en) 2008-09-30
TR200602095T2 (tr) 2007-02-21
CA2425809A1 (en) 2002-04-18
EA006945B1 (ru) 2006-06-30
CZ20031307A3 (cs) 2003-10-15
EE200300179A (et) 2003-08-15
KR20030041164A (ko) 2003-05-23
NO20031642D0 (no) 2003-04-10
MXPA03003144A (es) 2004-12-06
IS6779A (is) 2003-04-11
WO2002030986A2 (en) 2002-04-18
AU1174702A (en) 2002-04-22
EP1326897A2 (de) 2003-07-16
BG107802A (bg) 2004-01-30
YU28503A (sh) 2006-05-25
HUP0302573A2 (hu) 2003-10-28
IL155340A0 (en) 2003-11-23
JP2004532608A (ja) 2004-10-28
SK5672003A3 (en) 2003-10-07
AU2002211747B2 (en) 2007-11-29
BR0114646A (pt) 2006-02-21
PL366307A1 (en) 2005-01-24
EA200300464A1 (ru) 2003-10-30
NZ525793A (en) 2008-04-30
TR200300478T2 (tr) 2004-10-21
NO20031642L (no) 2003-06-13
CN1547590A (zh) 2004-11-17
US20040058394A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
GEP20063752B (en) Humanized Anti-LT-Beta-R Antibodies
RS52484B (en) CD40 ANTIBODIES
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ568403A (en) CD20-specific antibodies and methods of employing same
ATE350478T1 (de) Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
DK0440146T3 (da) Fremstilling og anvendelse af genbanker af syntetiske humane antistoffer ("syntetiske humane antistof-biblioteker").
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
NZ604082A (en) Method for treating multiple sclerosis
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ614727A (en) Human antibodies that bind human tnfa
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
EA200200503A1 (ru) Способ лечения ревматоидного артрита
RU2602878C3 (ru) Конъюгаты "производное калихеамицина-носитель"
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PE20061166A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-17 humana
NZ607711A (en) Antibodies directed to her-3 and uses thereof
SG156547A1 (en) Human monoclonal antibodies to ctla-4
FI3740504T3 (fi) CD70-yhdistelmähoito
ES2187529T3 (es) Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal.
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
NZ596381A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof